GSK plc: An Undervalued Vaccine Behemoth That Is Resuming Growth; Buy

Leon Neal GSK overview GSK plc (NYSE:GSK) is a British multinational “Big Pharma” established in 2000 by the merger of Glaxo Wellcome and SmithKline Beecham. It possesses a leading position in the traditional vaccine (Not mRNA vaccine) and HIV area. In fact, GSK produced the first FDA-approved malaria vaccine. Currently, its best-selling vaccine is Shingrix for Shingles, which netted ~$4.33 billion in sales in 2023 and is rapidly growing still, as it just started to enter developing markets. On the other hand, GSK faces significant litigation risk as a result of its ongoing Zantac dispute. In this article, I will…